In Vivo Efficacy of an Injectable Microsphere-Hydrogel Ocular Drug Delivery System

Osswald, Christian R.; Guthrie, Micah J.; Avila, Abigail; Valio, Joseph A.; Mieler, William F.; Kang-Mieler, Jennifer J.

doi:10.1080/02713683.2017.1302590

Cited by 53 publications

(50 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By embedding anti-VEGF filled PLGA microspheres in a thermo-responsive PNIPAAm-PEG-diacrylate hydrogel, Osswald et al were able to achieve a sustained release of Ranibizumab (Lucentis™) and Aflibercept (Eylea™) for almost 200 days in vitro [105]. Bioactivity of the anti-VEGF agents was also retained as evidenced by the significantly smaller CNV lesion areas in the treated CNV rat models of the study [99].…”

Section: Hydrogels For Sustained Delivery Of Anti-vegfmentioning

confidence: 97%

See 1 more Smart Citation

Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases

Seah

Zhao

Lin

et al. 2020

Eye

View full text Add to dashboard Cite

Anti-vascular endothelial growth factors (anti-VEGF) have become the most common treatment modality for many retinal diseases. These include neovascular age-related macular degeneration (n-AMD), proliferative diabetic retinopathy (PDR) and retinal vein occlusions (RVO). However, these drugs are administered via intravitreal injections that are associated with sight-threatening complications. The most feared of these complications is endophthalmitis, a severe infection of the eye with extremely poor visual outcomes. Patients with retinal diseases typically have to undergo multiple injections before achieving the desired therapeutic effect. Each injection incurs the risk of the sight-threatening complications. As such, there has been great interest in developing sustained delivery platforms for anti-VEGF agents to the posterior segment of the eye. In recent years, there have been various strategies that have been conceptualised. These include non-biodegradable implants, nano-formulations and hydrogels. In this review, the barriers of drug delivery to the posterior segment of the eye will be explained. The characteristics of an ideal sustained delivery platform will then be discussed. Finally, the current available strategies will be analysed with the above-mentioned characteristics in mind to determine the advantages and disadvantages of each sustained drug delivery modality. Through the above, this review attempts to provide an overview of the sustained delivery platforms in their various phases of development.These authors contributed equally: Ivan Seah Yu Jun, Zhao Xin Xin 1234567890();,:1234567890();,:

show abstract

Section: Hydrogels For Sustained Delivery Of Anti-vegfmentioning

confidence: 97%

“…Most hydrogel platforms have not only shown to be biocompatible but also allow a sustained release of bioactive anti-VEGF to the retina for durations of multiple months [91,92,[98][99][100][101][102] (Table 2). Yu et al developed a hydrogel system comprised of natural polymers.…”

Section: Hydrogels For Sustained Delivery Of Anti-vegfmentioning

confidence: 99%

Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases

Seah

Zhao

Lin

et al. 2020

Eye

View full text Add to dashboard Cite

show abstract

“…They are also useful for circumventing the need for frequent repeat injections—which presents several risks and complications to patients—by acting as a drug depot even for unstable protein molecules [ 140 ]. There are a number of in-situ gelling systems reported for ocular delivery of proteins [ 225 , 300 , 301 , 302 , 303 , 304 , 305 , 306 , 307 , 308 ]. Xue et al [ 305 ] developed thermosensitive gels of anti-VEGF drugs (bevacizumab and aflibercept) using a PEG-polypropylene glycol (PPG)-PCL multiblock copolymer (hydrophilic–hydrophobic biodegradable copolymer) [ 305 ].…”

Section: Polypeptide Deliverymentioning

confidence: 99%

Injectables and Depots to Prolong Drug Action of Proteins and Peptides

et al. 2020

View full text Add to dashboard Cite

Proteins and peptides have emerged in recent years to treat a wide range of multifaceted diseases such as cancer, diabetes and inflammation. The emergence of polypeptides has yielded advancements in the fields of biopharmaceutical production and formulation. Polypeptides often display poor pharmacokinetics, limited permeability across biological barriers, suboptimal biodistribution, and some proclivity for immunogenicity. Frequent administration of polypeptides is generally required to maintain adequate therapeutic levels, which can limit efficacy and compliance while increasing adverse reactions. Many strategies to increase the duration of action of therapeutic polypeptides have been described with many clinical products having been developed. This review describes approaches to optimise polypeptide delivery organised by the commonly used routes of administration. Future innovations in formulation may hold the key to the continued successful development of proteins and peptides with optimal clinical properties.

show abstract

“…This type of thermosensitive hydrogel has been widely investigated for various biomedical applications (e.g., drug delivery, wound healing, tissue engineering) . A recent study reported a controlled and extended release of anti‐VEGFs from PNIPAM‐thermosensitive hydrogel to effectively treat laser‐induced choroidal neovascularization . Following a single intravitreal injection, PNIPAM thermosensitive hydrogel is regarded as safe, biocompatible, and well tolerated with no long‐term adverse system effects during a 12‐week study.…”

Section: Ophthalmic Hydrogel Systemmentioning

confidence: 99%

Stimulus‐Responsive Hydrogel for Ophthalmic Drug Delivery

Lin

Lei

Shi

et al. 2019

Macromolecular Bioscience

View full text Add to dashboard Cite

Blindness and vision impairment are major global health problems. Effective ophthalmic drug delivery poses a significant challenge because of protective physiological barriers and various biological clearance mechanisms that result in extremely low ocular bioavailability. Over the past several decades, several safe and effective ophthalmic drug delivery approaches have been promoted to combat these problems and to improve ocular bioavailability. Among these approaches, the stimulus‐responsive hydrogel for topical drug delivery has gained increasing attention because of its prolonged drug retention at the local site and enhanced ocular bioavailability. This review summarizes and presents recent advances and perspectives of a stimulus‐responsive hydrogel for ophthalmic drug delivery.

show abstract

In Vivo Efficacy of an Injectable Microsphere-Hydrogel Ocular Drug Delivery System

Cited by 53 publications

References 36 publications

Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases

Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases

Injectables and Depots to Prolong Drug Action of Proteins and Peptides

Stimulus‐Responsive Hydrogel for Ophthalmic Drug Delivery

Contact Info

Product

Resources

About